Tohoku University · International Research Institute of Disaster Science · 助教

Research keywordsantiviral drug discovery・HIV-1 protease inhibitors・integrase inhibitors・SARS-CoV-2 main protease・adenovirus antivirals・RNA aptamer sensors

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological EvaluationArun K. Ghosh, Heather L. Osswald, Kristof Glauninger, Johnson Agniswamy, Yuan-Fang Wang, Hironori Hayashi, Manabu Aoki, Irene T. Weber, Hiroaki Mitsuya
• Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.Amano M, Salcedo-Gómez PM, Yedidi RS, Zhao R, Hayashi H, Hasegawa K, Nakamura T, Martyr CD, Ghosh AK, Mitsuya H
• Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1JR-FL in the setting of post-exposure prophylaxis in NOD/SCID/Jak3-/- mice transplanted with human PBMCs.Hiromi Ogata-Aoki, Nobuyo Higashi-Kuwata, Shin-Ichiro Hattori, Hironori Hayashi, Matthew Danish, Manabu Aoki, Chiemi Shiotsu, Yumi Hashiguchi, Akinobu Hamada, Hisataka Kobayashi, Hironobu Ihn, Seiji Okada, Hiroaki Mitsuya
• Construction of ribonucleopeptide-based fluorescent sensors for biologically active amines.Hasegawa T, Hayashi H, Morii T

• 機能と構造が導く薬剤耐性の克服2026 · 2026年4月 ～ 2029年3月
• 新規SARS-CoV-2 Mpro阻害剤TKB245の臨床応用を前提とした非臨床試験2022 · 2022年4月 ～ 2023年3月
• 新規高活性触媒機能付与型核酸医薬によるCOVID-19感染症治療薬の開発2021 · 2021年4月 ～ 2022年3月
• 新規高活性触媒機能付与型核酸医薬によるCOVID-19感染症治療用創薬技術の開発2021 · 2021年4月 ～ 2022年3月

• Official profile